Giga Carbon Neutrality (GCN) Announces Contract for 2520 Battery Powered EV Trucks in China, and a Framework Agreement for up to 8000 More Over the Next Three Years, Continuing the Global Lead
15.12.2021 16:53:00 EET | Business Wire | Press release
Giga Carbon Neutrality (GCN), the Canadian and US based clean commercial transportation and technology company, today announced that it has secured a contract to supply 2520 battery powered EV heavy trucks to Guohua Environmental Energy Industry Development Company (Guohua) to fulfill orders on behalf of a large Chinese State owned mining company. In addition, both parties have also entered into a framework agreement for up to 8,000 units of New Energy Vehicles (NEV) including battery EV heavy trucks and logistics vehicles for the mining industry. GCN will provide financial solutions for Guohua’s customers. The first batch of 20 Battery Electric Vehicles is due off the production line in the first half of 2022.
The GCN trucks will be produced in a strategic partnership with Xuzhou Construction Machinery Group (XCMG) and Guohua, who will be supplying the cold weather high performance batteries.
In November 2021, GCN announced its intention to launch a full range of 21 battery-electric and hydrogen fuel-cell vehicles by the end of 2023, which will be configurable to a wide range of commercial use cases. The first vehicles are available to order now for delivery in 2022.
Marty Wade, CEO at Giga Carbon Neutrality, comments: “Coming just a week after the announcement of the contract for 200 Hydrogen Fuel Cell powered trucks, this contract for 2520 battery electric trucks, plus the framework agreement for up to 8000 more, puts us at the forefront of the new energy commercial vehicle sector.”
See GCN’s Hydrogen Tractor on the road in China at https://youtu.be/6MWfu8zswTo
About Giga Carbon Neutrality (www.gigacarbonneutrality.com)
Giga Carbon Neutrality is a clean energy trucking and technology company with a supporting ‘Energy-as-a-Service’ (EaaS) offering that makes running clean, reliable vehicle fleets easy for industrial and commercial transportation companies. GCN'S portfolio includes battery-electric and hydrogen fuel cell vehicles, clean energy storage, charging and refueling infrastructure, and specialist financing to support the transition to zero-emission vehicles.
About Guohua Environmental Energy Industry Development Company Ltd
Guohua Environmental Energy Industry Development Co., LTD is a high-tech company with R&D and production capacity of new energy battery materials, lithium batteries, solid-state batteries, BMS, PACK system and motor drive system. With registered capital of RMB 50 million, it has a strong research team and a global research network. It also owns multiple research platforms for lithium-ion battery materials, lithium battery and PACK system.
About XCMG (www.xcmg.com)
XCMG is the iconic brand of the equipment industry of China. XCMG group, 78 years of history, is a multinational enterprise giant. No. 1 in Chinese construction machinery industry, top 3 in the industry in the whole world, XCMG has been supplying the products to over 187 countries and regions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211215005575/en/
Contact information
For more information:
James Taylor | Roaring Mouse Public Relations
E: james.taylor@roaringmousepr.com
T: +44 (0)1246 938833
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom